Dale Muzzey

Chief Scientific Officer Myriad

Seminars

Tuesday 3rd February 2026
Introducing Myriad’s Ultra-Sensitive Tumor Informed MRD Assay
9:30 am

Join this deep-dive session to understand how ultra-sensitive, tumor-informed MRD testing is being applied across real clinical and development settings. Hear how leading experts are translating MRD data into actionable decisions across patient management, trial design, and therapeutic development. Walk away with a clear view of where MRD delivers value today and how to apply it across your own programs.

Dale Muzzey